Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody.
A murine hybridoma monoclonal anti-T-cell antibody was given to a patient with advanced cutaneous T cell lymphoma. The patient tolerated seventeen treatment courses over ten weeks without symptoms of toxicity. Each treatment caused a reduction in circulating T cells which reached a stable level after two weeks of therapy. Antigenic modulation was observed after each treatment but was fully reversed within three to four days; therefore the treatment was given twice weekly. Monoclonal antibody produced a striking clinical response in skin, lymph nodes, and blood but complete remission was not achieved. Since the remaining disease was antigen positive, failure to eradicate all tumour cells was not a result of immunoselection. At no time did the patient show an antimouse immune response.
D000368:Aged; D000906:Antibodies / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D006801:Humans; D006822:Hybrid Cells / Q000276:immunology; D008223:Lymphoma / Q000473:pathology / Q000628:therapy*; D008297:Male; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000961:Antilymphocyte Serum